DeciBio Liquid Biopsy Weekly Digest
July 10th, 2020
AnchorDx is launching a clinical study through their partnership with Johnson &m Johnson. The study will enroll 3000 patients with lung nodules identified by a CT scan and will be used to determine if Anchor's ~$100 methylation based blood test has clinical utility in detecting lung cancer early by differentiating benign nodules from malignant nodules.
Angle announced that Parsortix, a CTC capture device, identified targetable mutations in metastatic breast cancer that were missed in single site biopsies. The company plans to file their FDA submission for Parsortix in Q3 2020. This announcement comes amidst other research movements for liquid biopsy in breast cancer, which is exciting since this cancer is known to be low shedding and difficult to develop assays for.
Canexia Health (formerly Contextual Genomics) is leading a consortium whose initiative is to improve testing and treatment of Canadian cancer patients during this pandemic. The project is called ACTT (Access to Cancer Testing and Treatment) and will offer Canexia's liquid biopsy test (Follow It) to recurrent or metastatic lung, breast, or colon cancer. Many patients have forgone genomic profiling during the corona pandemic out of fear of contraction. Other patients are facing long wait times to get surgery due to hospital congestion and may not be able to have a tissue biopsy collected. Time is critical in cancer care and having access to targeted therapies could improve patient outcomes. The consortium is using LBx to help alleviate the complications caused by the pandemic and could have long lasting impacts on cancer care.
